Image credit Weight loss is an incredible journey; if you’ve been through it, you know how frustrating and overwhelmin ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

GLP-1 drugs such as Ozempic and Wegovy are providing new challenges for diet brands and gyms, who have seen a surge in demand ...

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market ... to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion ...

Rice University is part of a multiuniversity research team that has secured an award of up to $34.9 million from the Advanced Research Projects Agency for Health (ARPA-H) to accelerate the development ...

A 2022 study suggests that GLP-1 agonists (like Ozempic and Wegovy ... but you don’t need to start out with an intense exercise program. Simply taking a walk every day can help with your weight loss ...

The announcement could shake up the market for such injections, since the shortage designation allowed compounding pharmacies ...

Franklin U.S. Low Volatility High Dividend Index ETF offers stability and income by focusing on low volatility and high ...

WTW's 2024 Best Practices in Healthcare Survey found that U.S. employers project their healthcare costs will increase by 7.7% ...